Baudax Bio Announces Corporate Update; Co. Says Phase 1/2a Clinical Study Of TI-168 In Hemophilia A with FVIII Inhibitors Projected To Begin In Q1 2024
Portfolio Pulse from Benzinga Newsdesk
Baudax Bio has announced a corporate update, stating that the Phase 1/2a clinical study of TI-168 in Hemophilia A with FVIII inhibitors is projected to begin in Q1 2024.
October 18, 2023 | 12:12 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Baudax Bio's announcement of the projected start of the Phase 1/2a clinical study of TI-168 in Q1 2024 could potentially impact the company's stock.
The announcement of a new clinical study is significant news for a pharmaceutical company like Baudax Bio. However, as the study is not set to begin until Q1 2024, the immediate impact on the company's stock may be limited. The long-term impact will depend on the results of the study.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 100